Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

253
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
253
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

759
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
759
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

250
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
250
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

469
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
469
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

486
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
486
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

282
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
282

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining genotoxic gut bacterial strains increases tumor burden and accelerates onset in a germ-free mouse model of colon carcinogenesis.

Cell reports·2026
Same author

Patients with Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-like Peptide-1 Receptor Agonist Therapy.

Clinical and translational gastroenterology·2026
Same author

15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.

Nature medicine·2026
Same author

Pre-Crohn's Disease Stool From Discordant Siblings Promotes the Development of Colitis in Germ-Free Mice.

Gastroenterology·2026
Same author

Long-read metagenomics for strain tracking after faecal microbiota transplant.

Nature microbiology·2025
Same author

Searching for the perfect match: MINDFUL trial pairs FMT and fiber for ulcerative colitis.

Med (New York, N.Y.)·2025

Related Experiment Video

Updated: Oct 29, 2025

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.0K

Enterococcus faecalis Glucosamine Metabolism Exacerbates Experimental Colitis.

Ting-Jia Fan1, Laura Goeser2, Kun Lu3

  • 1Center for Gastrointestinal Biology and Disease, Chapel Hill, North Carolina; Department of Microbiology and Immunology, Chapel Hill, North Carolina.

Cellular and Molecular Gastroenterology and Hepatology
|July 11, 2021
PubMed
Summary

Carbohydrate metabolism by gut bacteria, particularly Enterococcus faecalis importing glucosamine, exacerbates intestinal inflammation in inflammatory bowel diseases (IBDs). This highlights a potential therapeutic target for IBDs.

Keywords:
Gene ExpressionInflammatory Bowel DiseasesPhosphotransferase System

More Related Videos

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection
09:49

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection

Published on: November 18, 2022

2.4K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

969

Related Experiment Videos

Last Updated: Oct 29, 2025

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

48.0K
Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection
09:49

Investigation of Microbial Cooperation via Imaging Mass Spectrometry Analysis of Bacterial Colonies Grown on Agar and in Tissue During Infection

Published on: November 18, 2022

2.4K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

969

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Inflammatory bowel diseases (IBDs) involve aberrant immune responses to gut bacteria.
  • Dietary carbohydrates influence gut microbiota and are linked to IBDs.
  • The role of luminal carbohydrates in IBD pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the impact of luminal carbohydrate metabolism by gut bacteria on intestinal inflammation.
  • To determine if carbohydrate metabolism by proinflammatory bacteria enhances their growth and worsens colitis.

Main Methods:

  • Colonization of germ-free mice (wild-type and IL-10 knockout) with bacterial consortia.
  • Assessment of colon inflammation via histology and cytokine secretion (IL-12/23p40).
  • Analysis of bacterial composition, gene expression, and luminal glucosamine levels.

Main Results:

  • A bacterial consortium induced severe colitis in IL-10 knockout mice, upregulating carbohydrate metabolism genes.
  • Enterococcus faecalis OG1RF, a proinflammatory strain, upregulated a glucosamine import system (OG1RF_11616-11610).
  • Increased luminal glucosamine during colitis and the OG1RF_11616 system worsened colitis via microbiota-dependent mechanisms.

Conclusions:

  • Luminal carbohydrate metabolism by specific gut bacteria contributes to IBD pathogenesis.
  • Targeting bacterial carbohydrate import, like glucosamine uptake, may offer novel therapeutic strategies for IBDs.
  • Further research into luminal carbohydrate-bacterial interactions is crucial for understanding and treating IBDs.